Peyrin-Biroulet, Laurent; Chamaillard, Mathias; Gonzalez, Florent; Beclin, Elodie; Decourcelle, Cecilia; Antunes, Laurent; Gay, Jérôme; Neut, Christel; Colombel, Jean-Frédéric; Desreumaux, Pierre
April 2007
Gut;Apr2007, Vol. 56 Issue 4, p577
Academic Journal
The article discusses the normal and pathophysiological functions of mesenteric white adipose tissue (WAT). WAT may play an important role in the inflammatory and fibrotic processes in Crohn's disease, a frequent and complex form of inflammatory bowel disease. The mesenteric fat may contribute to the increase C-reactive protein production. Moreover, it could also influence the gut barrier function by promoting the innate immune response to the gut flora.


Related Articles

  • Defective Apoptosis in Intestinal and Mesenteric Adipose Tissue of Crohn’s Disease Patients. Dias, Cilene Bicca; Milanski, Marciane; Portovedo, Mariana; Horita, Vivian; Ayrizono, Maria de Lourdes Setsuko; Planell, Núria; Coy, Cláudio Saddy Rodrigues; Velloso, Lício Augusto; Meirelles, Luciana Rodrigues; Leal, Raquel Franco // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Background: Crohn’s disease (CD) is associated with complex pathogenic pathways involving defects in apoptosis mechanisms. Recently, mesenteric adipose tissue (MAT) has been associated with CD ethiopathology, since adipose thickening is detected close to the affected intestinal area....

  • New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets. Stefanelli, Tommaso; Malesci, Alberto; Repici, Alessandro; Vetrano, Stefania; Danese, Silvio // Current Drug Targets;May2008, Vol. 9 Issue 5, p413 

    The etiopathogenesis of Crohn's disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an...

  • Mesenteric fat in Crohn's disease: the hot spot of inflammation? Siegmund, Britta // Gut;Jan2012, Vol. 61 Issue 1, p3 

    The article comments on two studies on fat and Crohn's disease including one on the role of mesenteric fat by Peyrin-Biroulet et al and fat tissues in various parts of a patient with CD by Zulian et al. Findings of the Peyrin-Biroulet et al study, it says, demonstrated the equal production of...

  • Efficacy of T2 in Active Crohn’s Disease: A Prospective Study Report. Qingsong Tao; Xinbo Wang; Zhiming Wang; Jieshou Li // Digestive Diseases & Sciences;Aug2007, Vol. 52 Issue 8, p1790 

    Abstract  To date few therapies have been shown to reliably prevent the evolution of Crohn’s disease (CD). The traditional Chinese medicine, Tripterygium wilfordii Hook F (TWHF), has both immunomodulatory and anti-inflammatory activities. Our aim was to investigate...

  • Certolizumab Pegol: In Crohn's Disease.  // BioDrugs;2007, Vol. 21 Issue 3, p195 

    â–´ Certolizumab pegol is a pegylated humanized Fab' fragment of an anti-tumor necrosis factor-a (TNFa) monoclonal antibody, which binds with high affinity to both membrane-bound and soluble TNFa and demonstrates high neutralizing potency for these factors. â–´ The elimination half-life...

  • Measuring disease activity in Crohn's disease: what is currently available to the clinician. D'Incà, Renata; Caccaro, Roberta // Clinical & Experimental Gastroenterology;2014, Vol. 7, p151 

    Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing-remitting clinical behavior and dominated by intestinal inflammation. Being a chronic disorder that with time develops into a disabling disease, it is important to monitor the severity of inflammation to...

  • Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire. Ruffolo, Cesare; Scarpa, Marco; Faggian, Diego; Basso, Daniela; D'Incà, Renata; Plebani, Mario; Sturniolo, Giacomo C.; Bassi, Nicolò; Angriman, Imerio; D'Incà, Renata; Bassi, Nicolò // Journal of Gastrointestinal Surgery;Jan2010, Vol. 14 Issue 1, p24 

    Background/aims: Fecal lactoferrin is the direct expression of intestinal inflammation in Crohn's disease (CD). The aim of this study was to analyze the in vivo intimate correlation between intestinal and systemic inflammation in CD patients in clinical remission following bowel...

  • ORATORY MARKERS IN IBD: MAGIC, OR UNNECESSARY TOYS? Vermeire, S.; Van Assche, G.; Rutgeerts, P. // Gut;Mar2006, Vol. 55 Issue 3, p426 

    Laboratory markers have been investigated in inflammatory bowel disease (IBD) for diagnostic and differential diagnostic purposes, for assessment of disease activity and risk of complications, for prediction of relapse, and for monitoring the effect of therapy. The introduction of biological...

  • A Subgroup of First-Degree Relatives of Crohn's Disease Patients Shows a Profile of Inflammatory Markers in the Blood Which Is More Typical of Crohn's Disease Patients Than of Normal Individuals. Efrat, Broide; Iris, Goren; Hongbin Wang; Eitan, Scapa; Yona, Keisari // Mediators of Inflammation;1/1/2006, Vol. 2006, Special section p1 

    Introduction. Family member with IBD is the greatest risk factor for developing the disease. The hematological profile of first-degree relatives (FDRs) of Crohn's disease (CD) patients was studied in order to identify healthy FDRs at risk to develop disease. Materials and methods. Thirty CD...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics